CareDx, Inc.: shareholders and insiders

CDNANASDAQHealthcare · Services-Medical Laboratories

Price

$73.72

November 16, 2026Market cap $3.8B

What Ploutos Investor adds for CareDx

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 14 fiscal years, from 2012
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 17, 2025 to Nov 16, 2026, from their own Form 4 filings.

39 Form 4s

Bought on the market

–

nobody

Sold on the market

$20M

8 people

From Nov 17, 2025 to Nov 17, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan84%
  • The rest16%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 17, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·no buys·sold $20M by 8 people

  • 2025: no buys, sold $139.8K by 1 person
  • 2026: no buys, sold $20M by 8 people
  • Nov 12, 2026Michael GoldbergDirector
    Kind10b5-1
  • Nov 12, 2026Michael GoldbergDirector
    Kind10b5-1
  • Nov 12, 2026Michael GoldbergDirector
    Kind10b5-1
  • Nov 12, 2026Keith KennedyCFO & COO
    Kind10b5-1
  • Nov 12, 2026Keith KennedyCFO & COO
    Kind10b5-1
  • Nov 12, 2026Keith KennedyCFO & COO
    Kind10b5-1
  • Nov 10, 2026George BickerstaffDirector
    Kind
  • Nov 10, 2026Jeffrey Adam NovackSecretary and General Counsel
    Kind10b5-1
  • Nov 10, 2026Jeffrey Adam NovackSecretary and General Counsel
    Kind10b5-1
  • Nov 10, 2026Jeffrey Adam NovackSecretary and General Counsel
    Kind10b5-1
  • Nov 6, 2026Jeffrey Adam NovackSecretary and General Counsel
    Kind
  • Nov 5, 2026Keith KennedyCFO & COO
    Kind10b5-1
  • Nov 5, 2026Keith KennedyCFO & COO
    Kind10b5-1
  • Nov 5, 2026Keith KennedyCFO & COO
    Kind10b5-1
  • Nov 5, 2026Keith KennedyCFO & COO
    Kind10b5-1
  • Nov 5, 2026Keith KennedyCFO & COO
    Kind10b5-1
  • Nov 5, 2026Keith KennedyCFO & COO
    Kind10b5-1
  • Nov 5, 2026Keith KennedyCFO & COO
    Kind10b5-1
  • Nov 5, 2026Keith KennedyCFO & COO
    Kind10b5-1
  • Nov 5, 2026Keith KennedyCFO & COO
    Kind10b5-1
  • Nov 3, 2026Fred E CohenDirector
    Kind
  • Nov 1, 2026Jeffrey Adam NovackSecretary and General Counsel
    Kind
  • Oct 2, 2026Michael GoldbergDirector
    Kind
  • Oct 1, 2026Jeffrey Adam NovackSecretary and General Counsel
    Kind
  • Oct 1, 2026John Walter Hanna JRPresident and CEO
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 8, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by CDNA's officers and directors from 2014 up to November 16, 2025, 12 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

2 Holders over 5%Nov 10, 2026 Latest filing
  • BlackRock, Inc.
    Share of class9.00%
  • State Street
    Share of class5.10%
Fell to 5% or less (4)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • Bamco3.75%Aug 14, 202613G/A
  • Gagnon Securities LLC4.40%Aug 7, 202613G/A
  • The Vanguard Group0.00%Mar 26, 202613G/A
  • ARK Investment Management LLC4.49%Feb 14, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Renaissance Technologies
    In the quarter+1.0%
  • D.E. Shaw
    In the quarter+30%
  • Citadel Advisors (Griffin)
    In the quarter+27%
  • Millennium Mgmt (Englander)
    In the quarter
  • AQR Capital
    In the quarter-30%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 13.1% of its shares outstanding were held short, +1.9% since the report before.

Shares held short
6.72M
13.1%
Since the report before6.59M on Sep 30, 2026
+1.9%
4.5
1.49M
More days to cover thanof 4,578 US-listed companies with enough volume
54%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 4.50M
  • Nov 15, 2023: Shares held short 3.89M
  • Nov 30, 2023: Shares held short 3.42M
  • Dec 15, 2023: Shares held short 3.15M
  • Dec 29, 2023: Shares held short 2.30M
  • Jan 12, 2024: Shares held short 2.37M
  • Jan 31, 2024: Shares held short 2.85M
  • Feb 15, 2024: Shares held short 3.60M
  • Feb 29, 2024: Shares held short 3.76M
  • Mar 15, 2024: Shares held short 4.36M
  • Mar 28, 2024: Shares held short 5.18M
  • Apr 15, 2024: Shares held short 4.69M
  • Apr 30, 2024: Shares held short 5.14M
  • May 15, 2024: Shares held short 5.31M
  • May 31, 2024: Shares held short 5.37M
  • Jun 14, 2024: Shares held short 5.36M
  • Jun 28, 2024: Shares held short 3.82M
  • Jul 15, 2024: Shares held short 3.92M
  • Jul 31, 2024: Shares held short 3.48M
  • Aug 15, 2024: Shares held short 3.21M
  • Aug 30, 2024: Shares held short 3.31M
  • Sep 13, 2024: Shares held short 3.66M
  • Sep 30, 2024: Shares held short 3.66M
  • Oct 15, 2024: Shares held short 3.48M
  • Oct 31, 2024: Shares held short 3.45M
  • Nov 15, 2024: Shares held short 3.07M
  • Nov 29, 2024: Shares held short 3.34M
  • Dec 13, 2024: Shares held short 3.12M
  • Dec 31, 2024: Shares held short 3.97M
  • Jan 15, 2025: Shares held short 4.39M
  • Jan 31, 2025: Shares held short 4.46M
  • Feb 14, 2025: Shares held short 4.78M
  • Feb 28, 2025: Shares held short 5.18M
  • Mar 14, 2025: Shares held short 5.74M
  • Mar 31, 2025: Shares held short 5.56M
  • Apr 15, 2025: Shares held short 6.05M
  • Apr 30, 2025: Shares held short 6.13M
  • May 15, 2025: Shares held short 6.56M
  • May 30, 2025: Shares held short 6.50M
  • Jun 13, 2025: Shares held short 6.28M
  • Jun 30, 2025: Shares held short 6.40M
  • Jul 15, 2025: Shares held short 6.40M
  • Jul 31, 2025: Shares held short 6.18M
  • Aug 15, 2025: Shares held short 6.47M
  • Aug 29, 2025: Shares held short 6.90M
  • Sep 15, 2025: Shares held short 6.48M
  • Sep 30, 2025: Shares held short 6.24M
  • Oct 15, 2025: Shares held short 6.05M
  • Oct 31, 2025: Shares held short 6.57M
  • Nov 14, 2025: Shares held short 6.96M
  • Nov 28, 2025: Shares held short 6.57M
  • Dec 15, 2025: Shares held short 6.26M
  • Dec 31, 2025: Shares held short 5.89M
  • Jan 15, 2026: Shares held short 5.58M
  • Jan 30, 2026: Shares held short 5.75M
  • Feb 13, 2026: Shares held short 6.08M
  • Feb 27, 2026: Shares held short 6.28M
  • Mar 13, 2026: Shares held short 6.52M
  • Mar 31, 2026: Shares held short 6.42M
  • Apr 15, 2026: Shares held short 6.40M
  • Apr 30, 2026: Shares held short 6.89M
  • May 15, 2026: Shares held short 6.51M
  • May 29, 2026: Shares held short 6.37M
  • Jun 15, 2026: Shares held short 8.43M
  • Jun 30, 2026: Shares held short 8.34M
  • Jul 15, 2026: Shares held short 6.19M
  • Jul 31, 2026: Shares held short 6.14M
  • Aug 14, 2026: Shares held short 5.79M
  • Aug 31, 2026: Shares held short 5.83M
  • Sep 15, 2026: Shares held short 6.30M
  • Sep 30, 2026: Shares held short 6.59M
  • Oct 15, 2026: Shares held short 6.72M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading45.3% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 45.3% of the shares in the reported trades were short sales, against 59.1% in the 14 before.

Last 14 sessionsOct 28, 2026 – Nov 16, 2026
45.3%
The 14 beforeOct 8, 2026 – Oct 27, 2026
59.1%
Change
-13.8 pts
Short sales a dayon average, of 642.0K shares
290.6K
More than atof 3,668 US-listed companies, same days
33%
Median of alleight in ten from 34.7% to 63.8%
50.3%
  • Oct 8, 2026: Short sales 61.8%
  • Oct 9, 2026: Short sales 48.1%
  • Oct 12, 2026: Short sales 54.5%
  • Oct 13, 2026: Short sales 65.6%
  • Oct 14, 2026: Short sales 59.1%
  • Oct 15, 2026: Short sales 69.1%
  • Oct 16, 2026: Short sales 58.4%
  • Oct 19, 2026: Short sales 69.6%
  • Oct 20, 2026: Short sales 64.8%
  • Oct 21, 2026: Short sales 40.2%
  • Oct 22, 2026: Short sales 57%
  • Oct 23, 2026: Short sales 57.4%
  • Oct 26, 2026: Short sales 46%
  • Oct 27, 2026: Short sales 70.5%
  • Oct 28, 2026: Short sales 65.9%
  • Oct 29, 2026: Short sales 54.1%
  • Oct 30, 2026: Short sales 48%
  • Nov 2, 2026: Short sales 49%
  • Nov 3, 2026: Short sales 34.5%
  • Nov 4, 2026: Short sales 40.7%
  • Nov 5, 2026: Short sales 30%
  • Nov 6, 2026: Short sales 41.7%
  • Nov 9, 2026: Short sales 51.5%
  • Nov 10, 2026: Short sales 56.3%
  • Nov 11, 2026: Short sales 55.2%
  • Nov 12, 2026: Short sales 44.2%
  • Nov 13, 2026: Short sales 42.1%
  • Nov 16, 2026: Short sales 34.6%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

2.62M Insiders' shares5.11% Of the company
  • John Walter Hanna JRPresident and CEO
    Directly644.9K
  • Abhishek JainChief Financial Officer
    Directly337.4K
  • Peter MaagDirector
    Directly308.8K
  • Alexander L JohnsonSee Remarks
    Directly285.0K
  • Keith KennedyCFO & COO
    Directly199.1K
  • Jessica MengChief Commercial Officer
    Directly159.0K
  • George BickerstaffDirector
    Directly149.1K
  • Fred E CohenDirector
    Directly140.1K
  • Jeffrey Adam NovackSecretary and General Counsel
    Directly96.6K
  • William A HagstromDirector
    Directly54.0K
  • Michael GoldbergDirector
    Directly48.5K
  • Christine CournoyerDirector
    Directly42.9K
  • Richard Bryan RiggsbeeDirector
    Directly39.3K
  • Arthur A TorresDirector
    Directly38.7K
  • Suresh GunasekaranDirector
    Directly37.2K
  • Hannah ValantineDirector
    Directly36.8K

A lower bound: it counts only the 16 officers and directors with a market trade since Nov 18, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 269 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

17 ETFs holding it4.30% The largest weight (ARKG)
  • ARKGARK Genomic Revolution ETF
    Weight in the fund4.30%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.34%
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund0.30%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.10%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.09%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.08%
  • SCHASchwab U.S. Small-Cap ETF
    Weight in the fund0.05%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.05%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.03%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.02%

17 of the 269 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

227 Managers, Q2 2026$1.5B Value of their positions
  • Q3 2025: Managers 188
  • Q4 2025: Managers 201
  • Q1 2026: Managers 193
  • Q2 2026: Managers 227

Institutional investors by quarter

The fund managers holding CDNA, quarter by quarter, from Q3 2014 to Q2 2025, 44 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 227 managers held 53.40M shares, worth $1.5B. During the quarter 54 opened a position, 20 closed one, 73 added and 68 trimmed.

The largest holders, Q2 2026

  • BlackRock
    In the quarter+6.5%
  • State Street
    In the quarter-11%
  • Vanguard Capital Management
    In the quarter+1.7%
  • Deerfield Management
    In the quarter-8.8%
  • ARK Investment Management
    In the quarter-12%
  • Boston Partners
    In the quarter+2.9%
  • Bamco
    In the quarter-42%
  • Gagnon Securities
    In the quarter+0.5%
  • Chevy Chase Trust Holdings
    In the quarter-4.4%
  • Geode Capital Management
    In the quarter+5.9%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do CareDx's filings show?

Who buys and sells is one part of CareDx's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about CDNA's shareholders

Didn't find what you were looking for?

Ask us
Have CDNA's insiders bought or sold?

From Jun 8, 2026 to Nov 16, 2026 CareDx's insiders bought 0 and sold $18M of shares on the market. 83% of the sales were under set 10b5-1 plans.

Which well-known managers hold CDNA?

5 of the managers we track held the shares on Sep 30, 2026. The largest position was Renaissance Technologies's, worth $82M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.